SCHEMBL1384146

SCHEMBL1384146

Cc1c(C(=O)Nc2ccc(S(C)(=O)=O)cc2)c[nH]c1-c1ccccc1C(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 5/20 0.59
PTPRC P08575 1/20 0.43
TRPV1 Q8NER1 1/20 0.42
AVPR2 P30518 2/20 0.41
GPR27 Q9NS67 2/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA5A P35218 1/20 0.40
CA9 Q16790 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
MT-CO2 P00403 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2358001 0.87 NR3C2 (0.60) NR3C2TRPV1AVPR2GPR27MAOA
SCHEMBL2541697 0.86 NR3C2 (0.54) NR3C2AVPR2GPR27LMNAALDH1A1
SCHEMBL30038582 0.85 CFTR (0.46) NR3C2PTPRCTRPV1PTGES
SCHEMBL27941141 0.82 LMNA (0.43) NR3C2PTPRCTRPV1LMNAMAPT
SCHEMBL2439584 0.79 NR3C2 (0.79) NR3C2PTPRCAVPR2GPR27MAOA
SCHEMBL1384488 0.78 AVPR2 (0.45) AVPR2GPR27MAOAMAOBMT-CO2
SCHEMBL17363955 0.78 NR3C2 (0.51) NR3C2PTPRCAVPR2GPR27MAOA
SCHEMBL1382627 0.78 NR3C2 (0.48) NR3C2AVPR2GPR27MAOAMAOB
SCHEMBL1384216 0.78 NR3C2 (0.55) NR3C2PTPRCLMNAMAPTTDP1
SCHEMBL28064850 0.77 NR3C2 (0.45) NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
JP-4703649-B2 2011-06-15 JP claimed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
US-20240239746-A1 PREPARATION METHOD FOR PYRROLE AMIDE COMPOUND SUNSHINE LAKE PHARMA CO., LTD. (CN) 2024-07-18 US disclosed
US-20240239746-A1 PREPARATION METHOD FOR PYRROLE AMIDE COMPOUND SUNSHINE LAKE PHARMA CO., LTD. (CN) 2024-07-18 US disclosed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
CN-102186817-B Atropisomers of (hydroxyalkyl) pyrrole derivatives 埃克塞利希斯股份有限公司 2017-05-17 CN disclosed
EP-2349997-B1 ATROPISOMERS OF (HYDROXYALKYL) PYRROLE DERIVATIVES EXELIXIS INC (US) 2015-08-12 EP disclosed
US-8754118-B2 Atropisomer of pyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-06-17 US disclosed
US-20140024696-A1 ATROPISOMER OF PYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-01-23 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 NR3C2 119/4885PTPRC 452/4885TRPV1 22/4885
US-20140024696-A1 ATROPISOMER OF PYRROLE DERIVATIVE CYP11B2, CYP11B1, PYCR1 NR3C2 13/4885PTPRC 2525/4885TRPV1 1854/4885
US-20240239746-A1 PREPARATION METHOD FOR PYRROLE AMIDE COMPOUND HPGDS, HRH4, FAAH NR3C2 1528/4885PTPRC 4756/4885TRPV1 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.